Company News
President and Chief Executive Officer since 2018, Rohan Hastie has helped usher North Carolina-based firm Metabolon into a new era of success in the fields of precision medicine and clinical metabolomics.
MORRISVILLE, N.C. – May 17, 2021 – Rohan F. Hastie, Ph.D., President & CEO, Metabolon, Inc. has been recognized as one of the top 50 healthcare technology CEOs for 2021 by The Healthcare Technology Report. The ranking includes leaders who are driving cutting-edge technologies and unique opportunities for transformative growth within their areas of expertise.
Dr. Hastie has been at the helm of Metabolon since 2018, when initiated the company’s efforts to dramatically expand awareness and application of metabolomics in the biopharma market, setting a vision of enlightening life and enabling a healthier world. Under Dr. Hastie’s leadership, the company as expanded its commercial client base and secured significant investor funding to fuel new R&D programs in machine learning, novel biomarker discovery and an expanded precision medicine platform. Metabolon continues to demonstrate to researchers how metabolomics can be performed at scale with precision and quality assurance to support biopharma throughout the drug development continuum.
“At Metabolon, we are leveraging all of our talents and capabilities to become a diversified leader in healthcare and enable our clients to make important scientific breakthroughs,” says Hastie. “Metabolomics is a valuable tool that supports researchers in understanding internal and external factors of disease to improve the health and well-being of people.”
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond individual genetic variation, capturing the combined impact of genetic and external factors, such as drugs, diet, lifestyle, and the microbiome, on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies. With 25 years of experience, 15,000+ client projects, 4,000+ scientific publication references, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques.
Metabolon’s Global Discovery Panel is powered by the world’s largest proprietary metabolomics reference library. Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management.
For more information, please visit metabolon.com and follow us on LinkedIn and Twitter.
Sean Iverson
VP, Global Marketing
siverson@metabolon.com
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.
Corporate Headquarters
617 Davis Drive, Suite 100
Morrisville, NC 27560
Mailing Address
P.O. Box 110407
Research Triangle Park, NC 27709
Phone
+1 (919) 572-1711
Fax
+1 (919) 572-1721
International Headquarters
Metabolon GmbH
Zeppelinstraße 3
85399 Hallbergmoos
Germany